Sino Biological 新冠病毒Spike重组蛋白 His标签 新冠S蛋白

1, Chen, Y; et al. Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production. Cell, PMID: 33171099
2, Gao, L; et al. The dichotomous and incomplete adaptive immunity in COVID-19 patients with different disease severity. Signal transduction and targeted therapy, PMID: 33686064
3, Dejnirattisai, W; et al. The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell, PMID: 33756110
4, Pradenas, E; et al. Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes. Med (New York, N.Y.), PMID: 33554155
5, Williams, WB; et al. Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. Cell, PMID: 34019795
6, Jennewein, MF; et al. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. Cell reports, PMID: 34237283
7, Tong, P; et al. Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike. Cell, PMID: 34332650
8, Nassir, N; et al. Single-cell transcriptome identifies FCGR3B upregulated subtype of alveolar macrophages in patients with critical COVID-19. iScience, PMID: 34458692
9, Kramer, KJ; et al. Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition. Cell reports, PMID: 34592170
10, Verma, A; et al. Monoclonal antibodies protect aged rhesus macaques from SARS-CoV-2-induced immune activation and neuroinflammation. Cell reports, PMID: 34706272
11, Langellotto, F; et al. A Modular Biomaterial Scaffold-Based Vaccine Elicits Durable Adaptive Immunity to Subunit SARS-CoV-2 Antigens. Advanced healthcare materials, PMID: 34605223 1
2, Shroff, RT; et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nature medicine, PMID: 34594036 1
3, Chang, X; et al. A Novel Double Mosaic Virus-like Particle-Based Vaccine against SARS-CoV-2 Incorporates Both Receptor Binding Motif (RBM) and Fusion Domain. Vaccines, PMID: 34835218 1
4, Wang, X; et al. Temporal transcriptomic analysis using TrendCatcher identifies early and persistent neutrophil activation in severe COVID-19. JCI insight, PMID: 35175937 1
5, Walters, JN; et al. Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates. Vaccine, PMID: 35428500 1
6, Chen, Y; et al. Immune recall improves antibody durability and breadth to SARS-CoV-2 variants. Science immunology, PMID: 35549298 1
7, Junker, D; et al. Antibody binding and ACE2 binding inhibition is significantly reduced for both the BA1 and BA2 omicron variants. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, PMID: 35717657 1
8, Zimmerman, O; et al. mRNA vaccine boosting enhances antibody responses against SARS-CoV-2 Omicron variant in individuals with antibody deficiency syndromes. Cell Reports Medicine, PMID: 35688161 1
9, Tzeng, TT; et al. A DNA vaccine candidate delivered by an electroacupuncture machine provides protective immunity against SARS-CoV-2 infection. NPJ vaccines, PMID: 35662254
20, Wang, C; et al. The Kinetics of SARS-CoV-2 Antibody Development Is Associated with Clearance of RNAemia. mBio, PMID: 35762593
21, Jia, L; et al. Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunity. Gut microbes, PMID: 36100957 2
2, Sano, K; et al. SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals. Nature communications, PMID: 36050304 2
3, LaSalle, TJ; et al. Longitudinal characterization of circulating neutrophils uncovers phenotypes associated with severity in hospitalized COVID-19 patients. Cell Reports Medicine, PMID: 36208629 2
4, Langel, SN; et al. Dam-Infant Rhesus Macaque Pairs to Dissect Age-Dependent Responses to SARS-CoV-2 Infection. ImmunoHorizons, PMID: 36547390 2
5, Carreño, JM; et al. An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination. Science translational medicine, PMID: 36791207 2
6, Jia, T; et al. Stable and durable antibody responses in SARS-recovered donors vaccinated with inactivated SARS-CoV-2 vaccine. Journal of medical virology, PMID: 36905115 2
7, Buffington, J; et al. Identification of nurse shark VNAR single-domain antibodies targeting the spike S2 subunit of SARS-CoV-2. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, PMID: 37191949 2
8, Zhou, F; et al. Impact of ageing on homologous and human-coronavirus-reactive antibodies after SARS-CoV-2 vaccination or infection. NPJ vaccines, PMID: 38378953 2
9, Jung, W; et al. SARS-CoV-2 infection prior to vaccination amplifies Fc-mediated humoral profiles in an age-dependent manner. Cell reports, PMID: 39213155
30, Tong, X; et al. Compartment-specific antibody correlates of protection to SARS-CoV-2 Omicron in macaques. iScience, PMID: 39224511
31, Barnett, C; et al. Impaired immune responses in the airways are associated with poor outcome in critically ill COVID-19 patients. ERJ Open Research, PMID: 38978558 3
2, Dolange, V; et al. A surrogate ELISA to select high titer human convalescent plasma for treating immunocompromised patients infected with SARS-CoV-2 variants of concern. The Journal of infectious diseases, PMID: 39749487 3
3, Carreño, JM; et al. XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies. mBio, PMID: 40042313